Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term comparison of luseogliflozin versus sitagliptin in type 2 diabetes with NAFLD/NASH
jRCTs031190238Active, not recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM) comparing Luseogliflozin arm with Sitagliptin arm (2 arms). Primary endpoint: Change in MRE value from baseline at 72 weeks post-administration. Started Aug 2020; status: active, not recruiting.
02
Drugs
luseogliflozinsitagliptin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031190238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190238.